 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | PBCAR19B / Precision BioSci, azercabtagene zapreleucel (PBCAR0191) / Precision BioSci
Another new INN: PBCAR0191 = azercabtagene zapreleucel. But wasn't $DTIL supposed to be switching focus to next-gen PBCAR19B? #ASH22 (Twitter) - Nov 3, 2022
- | PBCAR19B / Precision BioSci
Trial completion date, Trial primary completion date: Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies (clinicaltrials.gov) - Jan 24, 2022
P1, N=24, Recruiting, Sponsor: Precision BioSciences, Inc.
Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: Jun 2022 --> Sep 2022
- || PBCAR19B / Precision BioSci
Enrollment open: Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies (clinicaltrials.gov) - May 6, 2021
P1, N=24, Recruiting, Sponsor: Precision BioSciences, Inc.
Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: Jun 2022 --> Sep 2022 Not yet recruiting --> Recruiting
- ||| PBCAR19B / Precision BioSci
CAR T-Cell Therapy: The @US_FDA cleared @PrecisionBioSci’s IND application for its CAR T-cell therapy PBCAR19B https://t.co/nsqMenVFwQ (Twitter) - Mar 4, 2021
- || PBCAR19B / Precision BioSci
New P1 trial: Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies (clinicaltrials.gov) - Dec 1, 2020
P1, N=24, Not yet recruiting, Sponsor: Precision BioSciences, Inc.